OncoMatch/Clinical Trials/NCT06485713
Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC
Is NCT06485713 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including trifluridine/tipiracil combined with fufuquitinib and fufuquitinib for metastatic colorectal cancer.
Treatment: trifluridine/tipiracil combined with fufuquitinib · fufuquitinib · Trifluridine/tipiracil — To evaluate the efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
advanced colorectal adenocarcinoma; At least 1 measurable lesion was present according to RECIST1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard first- and second-line treatment
who had failed standard first - and second-line treatment
Lab requirements
Blood counts
Hemoglobin ≥90g/L; Absolute count of neutrophils (ANC) ≥1.5×10^9/L; Platelet ≥100×10^9/L
Kidney function
Serum creatinine (CR) <1.5 ULN or creatinine clearance (CCR) ≥50ml/min
Liver function
ALT and AST ≤2.5 ULN; ALP ≤2.5 ULN (if liver metastases ≤5 ULN); Total bilirubin (TBIL) < 1.5 ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50%
Good organ function, laboratory tests meet the following criteria: Hemoglobin ≥90g/L; ANC ≥1.5×10^9/L; Platelet ≥100×10^9/L; ALT and AST ≤2.5 ULN; ALP ≤2.5 ULN (if liver metastases ≤5 ULN); Total bilirubin (TBIL) < 1.5 ULN; Serum creatinine (CR) <1.5 ULN or creatinine clearance (CCR) ≥50ml/min; Serum albumin ≥30g/L; INR, PT, APTT ≤1.5 ULN; TSH ≤ULN; LVEF ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify